Literature DB >> 17004102

Acute morphological sequelae of photodynamic therapy with 5-aminolevulinic acid in the C6 spheroid model.

Pitr Zelenkov1, Reinhold Baumgartner, Karl Bise, Michael Heide, Richard Meier, Susanne Stocker, Ronald Sroka, Roland Goldbrunner, Walter Stummer.   

Abstract

OBJECTIVE: Aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) may represent a treatment option for malignant brain tumors. We used a three-dimensional cell culture system, the C6 glioma spheroid model, to study acute effects of PDT and how they might be influenced by treatment conditions.
METHODS: Spheroids were incubated for 4 h in 100 microg/ml ALA in 5% CO(2) in room air or 95% O(2) with subsequent irradiation using a diode laser (lambda = 635 nm, 40 mW/cm(2), total fluence 25 J/cm(2)). Control groups were "laser only", "ALA only", and "no drug no light". Annexin V-FITC, a marker used for detection of apoptosis, propidium iodide (PI), a marker for necrotic cells and H 33342, a chromatin stain, were used for morphological characterization of PDT effects by confocal laser scanning and fluorescence microscopy. Hematoxylin-eosin staining and TdT-FragEL (TUNEL) assay were used on cryosections. Growth kinetics were followed for 8 days after PDT.
RESULTS: PDT after incubation in 5% CO(2) provided incomplete cell death and growth delay in spheroids of >350 microm diameter. However, complete cell death and growth arrest occurred in smaller spheroids (<350 microm). Incubation in 95% O(2) with subsequent PDT resulted in complete cell death and growth arrest regardless of spheroid size. In incompletely damaged spheroids viable cells were restricted to spheroid centers. The rate of cell death in all control groups was negligible. Cell death was accompanied by annexin/PI costaining, but there was also evidence for annexin V-FITC staining without PI uptake.
CONCLUSIONS: PDT of experimental glioma results in rapid and significant cell death that could be verified as acute necrosis immediately after irradiation. This effect depended on O(2) concentration and spheroid size.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17004102     DOI: 10.1007/s11060-006-9252-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  46 in total

1.  Repetitive 5-aminolevulinic acid-mediated photodynamic therapy on human glioma spheroids.

Authors:  Steen J Madsen; Chung-Ho Sun; Bruce J Tromberg; Henry Hirschberg
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

2.  In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid.

Authors:  W Stummer; S Stocker; A Novotny; A Heimann; O Sauer; O Kempski; N Plesnila; J Wietzorrek; H J Reulen
Journal:  J Photochem Photobiol B       Date:  1998-09       Impact factor: 6.252

3.  Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence.

Authors:  W Stummer; S Stocker; S Wagner; H Stepp; C Fritsch; C Goetz; A E Goetz; R Kiefmann; H J Reulen
Journal:  Neurosurgery       Date:  1998-03       Impact factor: 4.654

4.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

5.  National survey of patterns of care for brain-tumor patients.

Authors:  M S Mahaley; C Mettlin; N Natarajan; E R Laws; B B Peace
Journal:  J Neurosurg       Date:  1989-12       Impact factor: 5.115

Review 6.  Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure.

Authors:  M van Engeland; L J Nieland; F C Ramaekers; B Schutte; C P Reutelingsperger
Journal:  Cytometry       Date:  1998-01-01

7.  Photodynamic therapy of human glioma spheroids using 5-aminolevulinic acid.

Authors:  S J Madsen; C H Sun; B J Tromberg; V P Wallace; H Hirschberg
Journal:  Photochem Photobiol       Date:  2000-07       Impact factor: 3.421

Review 8.  Programmed cell death in cerebral ischemia.

Authors:  S H Graham; J Chen
Journal:  J Cereb Blood Flow Metab       Date:  2001-02       Impact factor: 6.200

Review 9.  5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review).

Authors:  Scott A Friesen; Geir Olav Hjortland; Steen J Madsen; Henry Hirschberg; Olav Engebraten; Jahn M Nesland; Qian Peng
Journal:  Int J Oncol       Date:  2002-09       Impact factor: 5.650

10.  Photodynamic therapy for recurrent supratentorial gliomas.

Authors:  P J Muller; B C Wilson
Journal:  Semin Surg Oncol       Date:  1995 Sep-Oct
View more
  4 in total

1.  Thiol/disulfide exchange is required for membrane fusion directed by the Newcastle disease virus fusion protein.

Authors:  Surbhi Jain; Lori W McGinnes; Trudy G Morrison
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

2.  Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report.

Authors:  Walter Stummer; Tobias Beck; Wolfgang Beyer; Jan Hendrik Mehrkens; Andreas Obermeier; Nima Etminan; Herbert Stepp; Jörg-Christian Tonn; Reinhold Baumgartner; Jochen Herms; Friedrich Wilhelm Kreth
Journal:  J Neurooncol       Date:  2007-11-23       Impact factor: 4.130

Review 3.  Nanocomposites for X-Ray Photodynamic Therapy.

Authors:  Zaira Gadzhimagomedova; Peter Zolotukhin; Oleg Kit; Daria Kirsanova; Alexander Soldatov
Journal:  Int J Mol Sci       Date:  2020-06-03       Impact factor: 5.923

4.  Effect of photodynamic therapy combined with torasemide on the expression of matrix metalloproteinase 2 and sodium-potassium-chloride cotransporter 1 in rat peritumoral edema and glioma.

Authors:  B O Li; Chao Meng; Xufeng Zhang; Damin Cong; Xin Gao; Wanlong Gao; Donghui Ju; Shaoshan Hu
Journal:  Oncol Lett       Date:  2016-02-09       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.